• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 5. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088

Introduction to 2-methyl-3-(4-methylpiperazin-1-yl)propan-1-amine (CAS No. 50846-06-5) and Its Emerging Applications in Chemical Biology

2-methyl-3-(4-methylpiperazin-1-yl)propan-1-amine, identified by the chemical identifier CAS No. 50846-06-5, is a compound of significant interest in the field of chemical biology and pharmaceutical research. This molecule, featuring a piperazine moiety and an amine functional group, has garnered attention due to its structural versatility and potential biological activity. The presence of a 4-methylpiperazine substituent enhances its pharmacological profile, making it a valuable scaffold for drug discovery initiatives.

The compound’s molecular structure consists of a propyl chain with a secondary amine at the terminal position, further modified by a methyl-substituted piperazine ring. This configuration imparts unique electronic and steric properties, enabling interactions with biological targets such as enzymes and receptors. Recent advancements in computational chemistry have facilitated the design of derivatives with optimized binding affinities, positioning 2-methyl-3-(4-methylpiperazin-1-yl)propan-1-amine as a promising candidate for therapeutic development.

In the realm of medicinal chemistry, the integration of 4-methylpiperazine into molecular frameworks has been associated with enhanced solubility and metabolic stability, critical factors for drug efficacy. Studies have demonstrated that this moiety can modulate neurotransmitter systems, particularly in the context of central nervous system (CNS) disorders. Emerging research indicates that derivatives of this compound may exhibit potential in treating conditions such as anxiety and depression by interacting with serotonin and dopamine pathways.

The synthesis of 2-methyl-3-(4-methylpiperazin-1-yl)propan-1-amine involves multi-step organic transformations, including reductive amination and nucleophilic substitution reactions. Advances in synthetic methodologies have enabled more efficient and scalable production processes, reducing costs and improving accessibility for research applications. The compound’s stability under various storage conditions further enhances its utility in long-term studies.

One of the most compelling aspects of 2-methyl-3-(4-methylpiperazin-1-yl)propan-1-amine is its role as a building block for more complex pharmacophores. Researchers have leveraged its scaffold to develop novel molecules with improved pharmacokinetic profiles. For instance, modifications at the propyl chain or the piperazine ring have yielded compounds with enhanced selectivity and reduced side effects. These findings underscore the importance of structure-based drug design in optimizing therapeutic agents.

The compound’s interaction with biological targets has been explored through both experimental and computational approaches. X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy have provided insights into its binding modes within protein active sites. Additionally, molecular dynamics simulations have helped predict conformational changes upon ligand binding, aiding in the rational design of next-generation derivatives.

In clinical research, 2-methyl-3-(4-methylpiperazin-1-yl)propan-1-amine has been investigated as a potential treatment for neurodegenerative diseases. Preliminary studies suggest that it may modulate oxidative stress pathways, offering protection against neuronal damage. Furthermore, its ability to cross the blood-brain barrier makes it an attractive candidate for CNS-targeted therapies. Ongoing trials are evaluating its efficacy in models of Parkinson’s disease and Alzheimer’s disease.

The environmental impact of synthesizing and handling 2-methyl-3-(4-methylpiperazin-1-yl)propan-1-amine has also been considered in recent research. Efforts to minimize waste generation and optimize reaction conditions align with green chemistry principles, ensuring sustainable practices in pharmaceutical development. These initiatives not only reduce costs but also contribute to environmental conservation.

Future directions in the study of 2-methyl-3-(4-methylpiperazin-1-yl)propan-1-am ine include exploring its potential in combination therapies. By pairing it with other bioactive molecules, researchers aim to achieve synergistic effects that could enhance treatment outcomes for multifaceted diseases. Additionally, investigating its role in precision medicine approaches may uncover personalized treatment strategies based on individual patient profiles.

The compound’s versatility extends beyond traditional pharmaceutical applications. It has shown promise in agrochemical formulations as well, where its structural features contribute to the development of novel pesticides with improved efficacy and reduced environmental persistence. This dual utility highlights the broad impact of synthetic chemistry on multiple sectors.

In conclusion, 2-methyl -3-( 4 -m ethyl piper azin -1 -y l )pr op an - 1 -am ine ( CAS No . 50846 -06 -5 ) represents a significant advancement in chemical biology and drug discovery . Its unique structural attributes , coupled with emerging research findings , position it as a cornerstone compound for future therapeutic developments . As scientific understanding evolves , so too will the applications and implications of this remarkable molecule. p >

• 57184-50-6(1-(2,2-Dimethylpropyl)piperazine)
• 5308-28-1(1-Isobutylpiperazine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)